RT Generic
T1 Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview
A1 Matito, A.
A1 Escribese, M. M.
A1 Longo, N.
A1 Mayorga, C.
A1 Luengo-Sanchez, O.
A1 Perez-Gordo, M.
A1 Matheu, V
A1 Labrador-Horrillo, M.
A1 Pascal, M.
A1 Seoane-Reula, M. E.
A1 Soc Espanola Alergologia & Inmunol, 
K1 Anaphylaxis
K1 &nbsp
K1 Antimediator therapy
K1 &nbsp
K1 Mast cell activation syndrome
K1 &nbsp
K1 Mast cell mediator release-related symptoms
K1 &nbsp
K1 Tryptase
K1 Indolent systemic mastocytosis
K1 European competence network
K1 Serum tryptase
K1 Peripheral-blood
K1 Venom immunotherapy
K1 Bone-marrow
K1 Human skin
K1 Kit d816v
K1 Anaphylaxis
K1 Disorders
AB The diagnosis of mast cell activation syndrome (MCAS) is defined by 3 criteria: (1) typical clinical signs and symptoms of acute, recurrent (episodic), and systemic mast cell activation (MCA); (2) increase in tryptase level to >20% + 2 ng/mL within 1-4 hours after onset of the acute crisis; and (3) response of MCA symptoms to antimediator therapy. Classification of MCAS requires highly sensitive and specific methodological approaches for the assessment of clonal bone marrow mast cells at low frequencies. The Spanish Network on Mastocytosis score has been used successfully as a predictive model for selecting MCAS candidates for bone marrow studies based on a high probability of an underlying clonal mast cell disorder. In this article, we propose a diagnostic algorithm and focus on the practical evaluation and management of patients with suspected MCAS.
PB Esmon publicidad s a, dept allergy & clin immunol, clin univ navarra
SN 1018-9068
YR 2021
FD 2021-01-01
LK https://hdl.handle.net/10668/24473
UL https://hdl.handle.net/10668/24473
LA en
DS RISalud
RD Apr 10, 2025